Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.32 |
| ▸ | HMGCR | P04035 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149957 | 1.00 | GABRA1 (0.39) | GABRA1GABRB2HTR1DHTR1BKDM4E | |
| SCHEMBL2150025 | 0.81 | GABRA1 (0.41) | GABRA1GABRB2HTR1DHTR1BKDM4E | |
| SCHEMBL2149363 | 0.81 | GABRA1 (0.41) | GABRA1GABRB2HTR1DHTR1BKDM4E | |
| SCHEMBL2150552 | 0.79 | DHFR (0.34) | LNPEP | |
| SCHEMBL2149565 | 0.78 | GABRA1 (0.46) | GABRA1GABRB2HTR1DHTR1BKDM4E | |
| SCHEMBL2149558 | 0.78 | GABRA1 (0.46) | GABRA1GABRB2HTR1DHTR1BKDM4E | |
| SCHEMBL1131718 | 0.76 | KDM4E (0.58) | KDM4ELMNAMAPK1LNPEPCYP2C19 | |
| SCHEMBL4918492 | 0.76 | KDM4E (0.58) | KDM4ELMNAMAPK1LNPEPCYP2C19 | |
| SCHEMBL1131722 | 0.76 | KDM4E (0.58) | KDM4ELMNAMAPK1LNPEPCYP2C19 | |
| SCHEMBL2149404 | 0.75 | GABRA1 (0.43) | GABRA1GABRB2HTR1DHTR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680328-B2 | Method for producing optically active cyclopropane carboxylic acid ester compound, asymmetric copper complex, and optically active salicylideneaminoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | ALDH18A1, ALDH3A1, DECR1 | GABRA1 346/4885GABRB2 566/4885HTR1D 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.